ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $340,067 | +728.6% | 16,318 | +533.0% | 0.00% | – |
Q4 2022 | $41,042 | -71.9% | 2,578 | -75.2% | 0.00% | – |
Q2 2022 | $146,000 | -92.7% | 10,390 | -87.9% | 0.00% | -100.0% |
Q4 2021 | $2,000,000 | -6.6% | 85,687 | -33.6% | 0.01% | -22.2% |
Q3 2021 | $2,142,000 | -76.2% | 128,978 | -40.8% | 0.01% | -86.4% |
Q3 2020 | $8,987,000 | +2277.5% | 217,864 | +2696.0% | 0.07% | +2100.0% |
Q2 2020 | $378,000 | -70.4% | 7,792 | -90.1% | 0.00% | -66.7% |
Q4 2018 | $1,275,000 | -95.3% | 78,845 | -94.0% | 0.01% | -92.6% |
Q3 2018 | $26,907,000 | +29.7% | 1,311,076 | -3.5% | 0.12% | +29.8% |
Q2 2018 | $20,749,000 | +27.5% | 1,358,793 | +87.5% | 0.09% | +38.2% |
Q1 2018 | $16,280,000 | +51.0% | 724,500 | +102.4% | 0.07% | +100.0% |
Q4 2017 | $10,778,000 | +32.5% | 357,958 | +22.7% | 0.03% | +3.0% |
Q2 2017 | $8,137,000 | -34.8% | 291,745 | -32.6% | 0.03% | -50.7% |
Q4 2016 | $12,479,000 | +4356.8% | 432,691 | +4226.9% | 0.07% | +3250.0% |
Q1 2016 | $280,000 | – | 10,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |